Authors Schmitz, M. ; Candelise, N. ; Kanata, E. ; Llorens, F. ; Thüne, K. ; Villar-Piqué, A. ; da Silva Correia, S.M. ; Dafou, D. ; Sklaviadis, T. ; Appelhans, D. ; Zerr, I.
Title Validation of poly(propylene imine) glycodendrimers towards their anti-prion conversion efficiency
Date 31.12.2019
Number 57976
Abstract Prion diseases, such as the sporadic Creutzfeldt–Jakob disease (sCJD), are a class of fatal neurodegenerative disorders. Currently, there is no efficient treatment or therapy available. Hence, the search for molecules that may inhibit the conversion of the cellular prion protein (PrPC) into its pathological counterpart PrPScrapie (PrPSc) is of great urgency. Here, we report the generation- and dose-dependent biological action of dense-shell poly(propylene imine) (PPI) glycodendrimers by using scrapie-infected neuroblastoma (ScN2a) cells and the real-time quaking-induced conversion assay (RT-QuIC) for validation of anti-prion efficiencies. Whereas the 2nd and 3rd generation of PPI glycodendrimers exhibited anti-prion conversion efficiency in ScN2a cells validated by RT-QuIC analysis, we observed that the 4th generation of glycodendrimers had shown no significant effect. Translational RT-QuIC studies conducted with human prions derived from sCJD patients indicated an anti-prion conversion effect (not on PrPRes degradation) of PPI glycodendrimers against human prions with the highest inhibitory activity of the 4th generation of PPI glycodendrimers towards prion aggregation compared to the 2nd and 3rd generation. In conclusion, our study highlights the potential of PPI glycodendrimers as therapeutic compounds due to their anti-conversion activity on human prions in a PrPSc strain depending manner.
Publisher Molecular Neurobiology
Citation Molecular Neurobiology 57 (2019) 1863-1874

Back to list